Analyst Reco. Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/07/2026 am IST			5-day change	1st Jan Change
56.50 ^USD	-1.05%		+1.16%	+28.91%

07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT

Analyst Reco.

07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
02/07	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
06/05	Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says	MT
02/03	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
11/02	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
02/02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
09/01	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
08/01	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
05/01	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
05/01	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
06/11	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
05/11	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
04/11	Exelixis Shares Fall After Guggenheim Downgrade	MT
03/11	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
22/25/22	Exelixis Shares Rise After Leerink Partners Upgrade	MT
21/25/21	Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38	MT
18/25/18	Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025	CI
30/25/30	UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating	MT
29/25/29	RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating	MT
29/25/29	Truist Cuts Price Target on Exelixis to $49 From $56, Keeps Buy Rating	MT
29/25/29	Morgan Stanley Lowers Price Target on Exelixis to $46 From $48, Keeps Overweight Rating	MT
15/25/15	Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating	MT
08/25/08	RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45	MT